Abstract: Presented herein are compositions and methods for preventing, reducing, delaying and treating a coronavirus infection and related disorders such as respiratory distress, disseminated intravascular coagulation, and central nervous system pathologies caused by coronavirus infection.
Type:
Grant
Filed:
January 11, 2022
Date of Patent:
March 26, 2024
Assignee:
ABREXA PHARMACEUTICALS, INC.
Inventors:
Jesus E. Villafranca, Charles Richard Kissinger
Abstract: In some aspects, isomyosmine or a pharmaceutically acceptable salt thereof may be administered to an individual for the treatment of diseases of the visual system.
Abstract: Described herein is the use sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPAR? agonist compound.
Abstract: The disclosure provides compositions and methods of treating diseases and conditions associated with phospholipase D (PLD) toxin. In particular, the methods include administering to a subject in need a pharmaceutical composition comprising a dicarboxylic acid ester.
Abstract: The present invention relates to a pharmaceutical composition comprising a therapeutically effective dose of Lenvatinib mesylate having sodium wherein the weight ratio of Lenvatinib mesylate to sodium carbonates ranges from 1:1.5 to 1:5.
Type:
Grant
Filed:
April 4, 2018
Date of Patent:
February 27, 2024
Assignee:
Synthon B.V.
Inventors:
Luis Nogueiras Nieto, Lisardo Alvarez Fernandez, Jose Velada Calzada, Rohit Kumar
Abstract: Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.
Abstract: The disclosure provides compositions and methods of inducing an analgesic effect. In particular, the methods include administering to a subject in need a pharmaceutical composition comprising a dicarboxylic acid ester.
Abstract: Methods of treating obesity include administering to a subject in need thereof an effective amount of a therapeutic agent capable of reversing an inhibition of a Na/K-ATPase in a small intestine of a subject, such as a basolateral membrane Na/K-ATPase. Administering the therapeutic agent can further decrease an amount of glucose transport and/or decrease an amount of salt absorption in the small intestine of the subject to thereby treat the obesity. Methods for screening for a compound useful for treating obesity include contacting a small intestine cell with an effective amount of a test compound, and detecting whether an activity level of a Na/K-ATPase in the small intestine cell is increased in the presence of the test compound. The test compound is then identified as a compound useful for the treatment of obesity if the activity level of the Na/K-ATPase is increased in the presence of the test compound.
Type:
Grant
Filed:
April 27, 2020
Date of Patent:
February 20, 2024
Assignee:
MARSHALL UNIVERSITY RESEARCH CORPORATION
Abstract: Described herein are pharmaceutical compositions comprising one or more fumarate esters and methods for treating multiple sclerosis subjects with the compositions where the incidence of gastrointestinal side effects is reduced compared to treatments comprising dimethyl fumarate (e.g., TECFIDERA®). In particular, described herein are oral pharmaceutical compositions comprising monomethyl fumarate in a liquid vehicle that have reduced gastrointestinal side effects.
Type:
Grant
Filed:
January 7, 2021
Date of Patent:
February 20, 2024
Assignee:
BANNER LIFE SCIENCES LLC
Inventors:
Franck S. F. Rousseau, Thomas Wallace Lategan, Tiffany Nicole Sprague, Jason Michael Vaughn, Justin Roy Hughey
Abstract: The present invention relates to a method for the management of dysmenorrhea involving administration of an estrogenic component which is preferably selected from the group consisting of estetrol and estetrol-like compounds. Estetrol-like compounds have been surprisingly found to be capable of mitigating dysmenorrhea, either when used alone or in combination with progestogenic components, and this to an extent surpassing the effect obtained with other compositions and with a favourable side-effect profile compared to currently available methods.
Abstract: The present disclosure provides compositions and methods for providing a health benefit to an animal utilizing ferulic acid and histidine. For example, a composition can contain ferulic acid and histidine in therapeutically effective amounts for providing the health benefit to the animal.
Type:
Grant
Filed:
August 10, 2021
Date of Patent:
February 13, 2024
Assignee:
SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Inventors:
Francois-Pierre Martin, Christian Darimont-Nicolau, Andreas Rytz
Abstract: Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of Compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne.
Type:
Grant
Filed:
April 20, 2021
Date of Patent:
February 13, 2024
Assignee:
Arena Pharmaceuticals, Inc.
Inventors:
Alan Glicklich, Maria Matilde Sanchez Kam, William R. Shanahan
Abstract: A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.
Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
Type:
Grant
Filed:
July 6, 2022
Date of Patent:
January 30, 2024
Assignee:
BEIGENE SWITZERLAND GMBH
Inventors:
Zhiwei Wang, Yunhang Guo, Gongyin Shi, Lai Wang
Abstract: Certain embodiments of the present disclosure provide pharmaceutical, unit-dose formulations, suitable for oral administration, that contain from 1% w/w to 20% w/w of a tafamidis-organic acid (such as adipic acid, glutaric acid, or fumaric acid) co-crystal; from 0.25% w/w to 2.5% w/w of an organic acid dissolution enhancer. Such formulations release, within 15 minutes in ¾ strength FeSSIF pH 5.8 or in FaSSIF+0.1% polysorbate 80 pH 6.5, at least 85% of the total tafamidis of the formulation.
Abstract: The present invention provides a method of treating depression disease in a treatment resistant patient comprising administering to a mucosal membrane of a patient an effective amount of a pharmaceutically acceptable composition comprising an effective amount of ketamine or dextromethorphan, wherein the mucosal administration of the ketamine or dextromethorphan containing composition allows for the mucosal absorption of the composition eliminating the digestive tract of the patient for effecting a rapid acting antidepressant treatment of the treatment resistant patient. This method includes administering the composition to a patient's mucosal membrane of a respiratory tract, a genitourinary tract, an oral tract, or rectal tract of the patient. A pharmaceutically acceptable composition comprising ketamine or dextromethorphan and a vehicle is disclosed. A biomarker for identifying a depressive disease is set forth.
Type:
Grant
Filed:
September 28, 2021
Date of Patent:
January 23, 2024
Assignee:
West Virginia University
Inventors:
Scott Pollard, Patrick Marshalek, Rae Matsumoto
Abstract: Methods of treating or ameliorating multiple sclerosis by the dihydroorotate dehydrogenase (DHODH) inhibitor vidofludimus or a pharmaceutically acceptable salt and/or a solvate, in particular a hydrate, thereof or a solvate, in particular a hydrate, of a pharmaceutically acceptable salt thereof, by administering to a human patient a therapeutically effective amount of the DHODH inhibitor, more specifically a daily dose of about 10 mg to about 45 mg.
Type:
Grant
Filed:
August 2, 2021
Date of Patent:
January 23, 2024
Assignee:
IMMUNIC AG
Inventors:
Andreas Mühler, Hella Kohlhof, Daniel Vitt
Abstract: The subject invention provides arsinothricin (AST) or salts thereof, and compositions comprising AST or a salt thereof for use as multi-stage antimalarials. The subject invention also provides methods for treating, inhibiting and/or preventing malaria infection and transmission by using AST or salts thereof, or compositions comprising AST or a salt thereof. Advantageously, AST or a salt thereof inhibits glutamine synthetase (GS) of malaria pathogens without exhibiting cytotoxicity to human host.
Type:
Grant
Filed:
July 10, 2023
Date of Patent:
January 23, 2024
Assignee:
THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
Inventors:
Masafumi Yoshinaga, Barry P. Rosen, Jun Li, Guodong Niu
Abstract: A composition comprising an active agent that inhibits acyl-coenzyme A:cholesterol acyltransferase (ACAT) is provided. With the composition, food intake can be suppressed, and/or body weight can be reduced, and/or metabolic disorders can be prevented and/or treated.